Avalon's Laboratory Services MSO Launches DNA Testing Kit For Predisposition To Opioid Addiction
Avalon's Laboratory Services MSO Launches DNA Testing Kit For Predisposition To Opioid Addiction
阿瓦隆實驗室服務MSO推出DNA檢測套裝，用於預測對阿片類藥物上癮的易感性。
Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC ("LSM") has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit . Avalon owns a 40% equity interest in LSM.
Avalon GloboCare Corp.（以下簡稱「公司」）（納斯達克：ALBT）是一家開發創新電芯技術，細胞療法和精準診斷的公司。今天宣佈，實驗室服務MSO，LLC（以下簡稱LSM）在美國推出了直接面向消費者的非侵入性DNA檢測，用於檢測可能存在的對阿片類藥物依賴的易感性。要購買或了解更多信息，請訪問www.labcorp.com/opioid-risk。Avalon在LSM擁有40％的股權。